专利信息

首页上页 1 2 3 4 5 6 7 8 下页尾页共 1991 条记录, 当前第3/200页。

专利标题：New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt

专利权人：ASTRAZENECA AB;

专利标题：HETEROCYCLIC COMPOUNDS AS CCR2b ANTAGONISTS

专利权人：ASTRAZENECA AB;

Compounds of formula (I) Q-L-W-C(=X)-Z-P wherein Q is a secondary or tertiary amine of the formula N(R1 )(R2)

专利标题：Forbedret produksjon av rosuvastatin kalsiumsalt

专利权人：ASTRAZENECA UK LTD;

专利标题：Compuesto 2-fluoro-11-(piperazin-1-il)dibenzo [b,f][1,4]tiazepina

专利权人：ASTRAZENECA AB;

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA SIGUENTE FORMULA: I DENDE Z SE DESCRIBE EN LA DESCRIPCION SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS COMPOSICIONES QUE LOS COMPRENDEN Y METODOS PARA TRATAR EL TRASTORNO BIPOLAR UN TRASTORNO DE ANSIEDAD UN TRASTORNO DE ESTADO DE ANIMO O LA ESQUIZOFRENIA U OTRO TRASTORNO PSICOTICO CON DICHOS COMPUESTOS.

专利标题：Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid

专利权人：ASTRAZENECA AB;

专利标题：Pharmaceutical Composition

专利权人：ASTRAZENECA UK LTD [GB];

The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

专利标题：Process for preparation of crystalline modification for use in preparation of esomeperazole sodium salt

专利权人：ASTRAZENECA AB;

PROBLEM TO BE SOLVED: To prepare a solution for crystallization of an esomeprazole sodium salt. SOLUTION: A process for preparation of the solution for crystallization of the esomeprazole sodium salt includes: a process (1) of suspending a potassium salt of esomeprazole in toluene and adding one molar equivalent acid HA as aqueous solution to adjust pH; a process (2) of adding an additional solution made of methanol to a toluene phase; and a process (3) of adding one molar equivalent sodium sal...

专利标题：REDUCED MASS METFORMIN FORMULATIONS

The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.

专利标题：(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives

专利权人：ASTRAZENECA AB;

The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

专利标题：BILAYER TABLET FORMULATIONS

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

当前查询条件: [专利权人组] 包含 '阿斯利康'

	查询范围	在当前结果中查询
!	专利类型	发明实用新型外观设计
!	公开号			CN1234
!	申请号			CN1234
!	专利标题		扩展	PHARMA
!	专利权人		扩展	pfizer
	发明人
!	申请日			yyyymmdd
!	公开日			yyyymmdd
	优先权号
!	摘要		扩展	PHARMA
	IPC			A01B

1. KR20130038949A	2013/4/18	KR20137005546	2005/6/20
专利标题：New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt 专利权人：ASTRAZENECA AB;

2. AU2013200955A1	2013/3/7	AU20130200955	2013/2/18
专利标题：HETEROCYCLIC COMPOUNDS AS CCR2b ANTAGONISTS 专利权人：ASTRAZENECA AB; Compounds of formula (I) Q-L-W-C(=X)-Z-P wherein Q is a secondary or tertiary amine of the formula N(R1 )(R2)

3. NO332971B1	2013/2/11
专利标题：Forbedret produksjon av rosuvastatin kalsiumsalt 专利权人：ASTRAZENECA UK LTD;

4. HN2010002683A	2013/1/15
专利标题：Compuesto 2-fluoro-11-(piperazin-1-il)dibenzo [b,f][1,4]tiazepina 专利权人：ASTRAZENECA AB; LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA SIGUENTE FORMULA: I DENDE Z SE DESCRIBE EN LA DESCRIPCION SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS COMPOSICIONES QUE LOS COMPRENDEN Y METODOS PARA TRATAR EL TRASTORNO BIPOLAR UN TRASTORNO DE ANSIEDAD UN TRASTORNO DE ESTADO DE ANIMO O LA ESQUIZOFRENIA U OTRO TRASTORNO PSICOTICO CON DICHOS COMPUESTOS.

5. EP1957081A4	2013/1/2
专利标题：Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid 专利权人：ASTRAZENECA AB;

6. US2012321712A1	2012/12/20	US201213475525	2012/5/18
专利标题：Pharmaceutical Composition 专利权人：ASTRAZENECA UK LTD [GB]; The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

7. JP2012246316A	2012/12/13	JP20120203798	2012/9/18
专利标题：Process for preparation of crystalline modification for use in preparation of esomeperazole sodium salt 专利权人：ASTRAZENECA AB; PROBLEM TO BE SOLVED: To prepare a solution for crystallization of an esomeprazole sodium salt. SOLUTION: A process for preparation of the solution for crystallization of the esomeprazole sodium salt includes: a process (1) of suspending a potassium salt of esomeprazole in toluene and adding one molar equivalent acid HA as aqueous solution to adjust pH; a process (2) of adding an additional solution made of methanol to a toluene phase; and a process (3) of adding one molar equivalent sodium sal...

8. US2012294936A1	2012/11/22	US201013509206	2010/11/12
专利标题：REDUCED MASS METFORMIN FORMULATIONS 专利权人：ASTRAZENECA UK LTD [GB];SQUIBB BRISTOL MYERS CO [US]; The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.

9. US20120289513A1	2012/11/15
专利标题：(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives 专利权人：ASTRAZENECA AB; The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

10. US2012282336A1	2012/11/8	US201013509210	2010/11/12
专利标题：BILAYER TABLET FORMULATIONS 专利权人：ASTRAZENECA UK LTD [GB];SQUIBB BRISTOL MYERS CO [US]; The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

下载范围

下载内容